AIRS, a company specializing in AI-based fracture surgery robot solutions, announced on the 11th that it had attracted 5 billion won in Series A investment. L&S Venture Capital participated in this investment round as the lead investor, and Reinvestment, O&Venture Investment, SL Investment, and Technology Guarantee Fund also participated.
Founded in 2020, Airs is a company that has developed an innovative AI surgical robot solution aimed at digitalizing fracture surgery. In conventional fracture surgery, multiple orthopedic specialists must interpret complex fracture conditions and perform surgery based on 2D X-ray images, which can lead to problems such as errors and excessive radiation exposure. Airs aims to solve these problems through AI robot technology, increase the accuracy of fracture surgery, and minimize radiation exposure.
In addition, Airs was selected as a company performing advanced bio-industry for the '2024 Strategic Technology Theme Project (Deep-tech Challenge Project, DCP)' by the Ministry of SMEs and Startups, and will receive 3.6 billion won in government subsidies. This project is a project that provides up to 10 billion won in funds to boldly challenge high-risk, high-performance research and development (R&D) fields through public-private cooperation, and a total of 6 companies were selected in national strategic technology fields with high global demand.
Airs plans to accelerate technology commercialization and global market expansion based on this investment and government subsidy. CEO Jeong Sang-hyun said, “This investment and government project selection are important milestones that have recognized Airs’ technology and growth potential.” He added, “We are currently establishing strategic partnerships in Singapore and India, and are also actively pursuing the US FDA approval process. We will become a company that leads the innovation of fracture surgery and the future of the healthcare industry.”
You must be logged in to post a comment.